Dyslipidemia and oxidative stress are causative factors for atherosclerosis changes in hemodialysis patients
Keywords:Cardiovascular disease, Hemodialysis, Lipid profile, Oxidative stress
Background: Cardiovascular disease is one of the leading cause of death in chronic kidney disease. The increased cardiovascular mortality observed in all stages of Chronic kidney disease patients. In hemodialysis cardiovascular mortality is more than 60%. In hemodialysis dyslipidemia contribute for the triggering of atherosclerosis. Endothelial dysfunction and oxidative stress are serves as main precursor for the progression of atherosclerosis. So the present study was aimed at studying lipid profile and oxidative stress in hemodialysis patients.
Methods: A cross sectional study carried out over a 2 year period in Department Nephrology and General Medicine OPD, MIMS, Vizianagaram, Andhra Pradesh, India. A total of 60 hemodialysis patients are included. In all the participants Lipid profile, SOD, MDA and Serum Nitrate was measured.
Results: There is a significantly increased levels of serum triglycerides and VLDL in hemodialysis patients when compared with Control. The HDL-C was significant Lower in hemodialysis patients when compared with control. The serum total cholesterol and LDL-C not shown any significant change. The Serum MDA and Serum Nitrate was significantly higher in hemodialysis patients compared with Control and it is statistically significant (p<0.001). Whereas the serum SOD value was significantly decreased in hemodialysis patients when compared with control and it is statistically significant (p<0.001).
Conclusion: Present study finding suggested that the incidence of atherosclerosis changes are higher in hemodialysis patients. Early detection and correction of atherosclerosis changes can help us to reducing the deleterious effects.
Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1(1):8-18.
Fried LF, Shlipak MG, Crump C, Kronmal RA, Bleyer AJ, Gottdiener JS, Kuller LH, Newman AB. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am College of Cardiol. 2003 Apr 16;41(8):1364-72.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clin Cardiol Epidemiol Preven. Hypertension. 2003;42(5):1050-65.
Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease. Effects on the cardiovascular system. Circulation. 2007;116(1):85-97.
Attman PO, Samuelsson O, Alaupovic P Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21(6):573-92.
Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35(5):852-62.
Sandau KB, Brüne B. Up-regulation of Bcl-2 by redox signals in glomerular mesangial cells. Cell Death Differ 2000;7(1):118-25.
Zou AP, Cowley AW Jr, Reactive oxygen species and molecular regulation of renal oxygenation. Acta Physiol Scand. 2003;179(3):233-41.
Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiol. Physiol Rev. 2007;87(1):245-313.
Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol. 2002;15(4):336-41.
Heitzer T, Schlinzig T, Krohn K. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104(22):2673-8.
Tiffany TO, Jansen JM, Burtis CA, Overton JB, Scott CD Enzymatic kinetic rate and end-point analyses of substrate, by use of a GeMSAEC fast analyzer. Clin Chem. 1972;18(8):829-40.
Bowers LD. Kinetic serum creatinine assays I. The role of various factors in determining specificity. Clin Chem. 1980;26(5):551-4.
Raju DSSK, Lalitha DL, Kiranmayi P. Observation of estimated GFR in the assessment of chronic kidney disease: application and practice. Asian J Pharm Clin Res. 2012;5(4):201-6.
Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470-5.
Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970; 11(6):583-95.
McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29(3):538-42.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18: 499-502.
Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys. 1984;21:130-2.
Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta. 1978;90(1):37-43.
Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin chemistry. 1995;41(6):892-6.
Huttunen JK, Pasternack A, Vanttinen T, Ehnholm C, Nikkila EA. Lipoprotein metabolism in patients with chronic uremia. Effect of hemodialysis on serum lipoproteins and postheparin plasma triglyceride lipases. Acta Med Scand. 1978;204: 211-8.
Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int. 1996;49(5):1360-71.
Liang K, Vaziri ND. Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure. Nephrol Dial Transplant. 1997;12(7):1381-6.
Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011;5:41-8.
Raju DSSK, Lalitha DL, Kiranmayi P. A Study of Lipid Profile and Lipid Peroxidation in Chronic Kidney Disease with Special Reference to Hemodialysis. J Clinic Res Bioeth. 2013;4(1):143.
Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14(6): 1462-6.
Guarnieri GF, Moracchiello M, Campanacci L, Ursini F, Ferri L. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl. 1978;2(8);S26-30.
Wesen AM. Determination of Resistin and Several Antioxidant in sera of patients with chronic renal failure. Australian J Basic and Applied Sciences. 2011;5(8):196-203.
Noleto Magalhaes RC, Guedes Borges de Araujo C, Batista de sousa Lima V, Machado Moita Neto J, Do Nascimento Nogueira N. Nutritional status of zinc and activity superoxide dismutase in chronic renal patients undergoing hemodialysis. Nutr Hosp. 2011;26(6):1456-61.
Toborek M, Wasik T, Drózdz M, Klin M, Mgner-Wróbel K. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 1992;41:1229-32.
Mu¨nzel T, Just H, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. In: Born GVR, Schwartz CJ (eds). Vascular Endothelium: Physiology, Pathology and Therapeutic Options. Schattauer: Stuttgart. 1997;205-20.